Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegafur/uracil - Taiho Pharmaceutical

Next Previous
Drug Profile

Tegafur/uracil - Taiho Pharmaceutical

Alternative Names: BMS 200604 01; Orzel; UFT; Uftoral

Latest Information Update: 02 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Merck KGaA; Otsuka Pharmaceutical; Taiho Pharmaceutical
  • Class Antineoplastics; Nitrogen mustard compounds; Pyrimidinones
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer
  • No development reported Cervical cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 29 Nov 2024 No development reported - Phase-III for Cervical cancer (Late-stage disease) in Japan (PO)
  • 05 Nov 2022 Adverse events and efficacy data from a phase III GOTIC-002 LUFT trial in Cervical cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 01 May 2021 Taiho Pharmaceutical completes a phase III trial for Colorectal cancer (Adjuvant therapy) in Japan, prior to May 2021 (PO) (UMIN000005594)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top